Scalable HPC & AI Infrastructure for COVID-19 Therapeutics

被引：3

作者：

Lee, Hyungro ^{[1
]}

Merzky, Andre ^{[1
]}

Tan, Li ^{[2
]}

Titov, Mikhail ^{[1
]}

Turilli, Matteo ^{[1
]}

Alfe, Dario ^{[3
]}

Bhati, Agastya ^{[3
]}

Brace, Alex ^{[4
]}

Clyde, Austin ^{[5
]}

Coveney, Peter ^{[3
]}

Ma, Heng ^{[4
]}

Ramanathan, Arvind ^{[4
]}

Stevens, Rick ^{[5
]}

Trifan, Anda ^{[6
]}

Van Dam, Hubertus ^{[2
]}

Wan, Shunzhou ^{[3
]}

Wilkinson, Sean ^{[7
]}

Jha, Shantenu ^{[1
,2
]}

机构：

[1] Rutgers State Univ, Piscataway, NJ 08854 USA

[2] Brookhaven Natl Lab, Upton, NY 11973 USA

[3] UCL, London, England

[4] Argonne Natl Lab, Lemont, IL USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Illinois, Champaign, IL USA

[7] Oak Ridge Natl Lab, Knoxville, TN USA

来源：

PROCEEDINGS OF THE PLATFORM FOR ADVANCED SCIENTIFIC COMPUTING CONFERENCE (PASC '21) | 2021年

基金：

美国能源部; 欧盟地平线“2020”;

关键词：

high-performance computing; machine learning; workflows; docking molecular dynamics; free energy estimation; COVID-19; FREE-ENERGY; PREDICTION;

D O I：

10.1145/3468267.3470573

中图分类号：

TP39 [计算机的应用];

学科分类号：

081203 ; 0835 ;

摘要：

COVID-19 has claimed more than 2.7 x 10(6) lives and resulted in over 124 x 10(6) infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation, characterize their performance, and highlight science advances that these capabilities have enabled.

引用

页数：13

共 50 条

[21] Identification and Development of Therapeutics for COVID-19
Rando, Halie M.
Wellhausen, Nils
Ghosh, Soumita
Lee, Alexandra J.
Dattoli, Anna Ada
Hu, Fengling
Byrd, James Brian
Rafizadeh, Diane N.
Lordan, Ronan
Qi, Yanjun
Sun, Yuchen
Brueffer, Christian
Field, Jeffrey M.
Ben Guebila, Marouen
Jadavji, Nafisa M.
Skelly, Ashwin N.
Ramsundar, Bharath
Wang, Jinhui
Goel, Rishi Raj
Park, Yoson
Boca, Simina M.
Gitter, Anthony
Greene, Casey S.
MSYSTEMS, 2021, 6 (06)
[22] COVID-19 Therapeutics and Considerations for Pregnancy
Joseph, Naima T.
Collier, Ai-Ris Y.
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2023, 50 (01) : 163 - 182
[23] RNA therapeutics for the treatment of Covid-19
Gawargi, Flobater
Sine, Laura
Hicks, Martin
FASEB JOURNAL, 2021, 35
[24] COVID-19 challenges and its therapeutics
Rehman, Sabi Ur
Rehman, Shaheed Ur
Yoo, Hye Hyun
BIOMEDICINE & PHARMACOTHERAPY, 2021, 142
[25] COVID-19 and Strategies for Its Therapeutics
Ma, Fayang
Gu, Tingxuan
Zhao, Simin
Liu, Kangdong
Dong, Zigang
CRITICAL REVIEWS IN IMMUNOLOGY, 2020, 40 (06) : 513 - 526
[26] Therapeutics for COVID-19: established and in development
Singh, Kasha P.
Sasadeusz, Joe
Lewin, Sharon R.
Audsley, Jennifer
MICROBIOLOGY AUSTRALIA, 2020, 41 (04) : 217 - 223
[27] Neutralizing Antibody Therapeutics for COVID-19
Hurt, Aeron C.
Wheatley, Adam K.
VIRUSES-BASEL, 2021, 13 (04):
[28] COVID-19 therapeutics for the pregnant patient
Triebwasser, Jourdan E.
Davies, Jill K.
Nestani, Ajleeta
SEMINARS IN PERINATOLOGY, 2024, 48 (04)
[29] HPC AI500 V3.0: A scalable HPC AI benchmarking framework
Jiang Z.
Luo C.
Gao W.
Wang L.
Zhan J.
BenchCouncil Transactions on Benchmarks, Standards and Evaluations, 2022, 2 (04):
[30] Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics
Sait, Afrah S.
Chiang, Teresa Po-Yu
Marr, Kieren A.
Massie, Allan B.
Cochran, Willa
Shah, Pali
Brennan, Daniel C.
Thomas, Alvin G.
Mehta Steinke, Seema
Permpalung, Nitipong
Shoham, Shmuel
Merlo, Christian
Jain, Tania
Boyarsky, Brian
Charnaya, Olga
Gurakar, Ahmet
Sharma, Kavita
Durand, Christine M.
Werbel, William A.
Huang, Chiung-Yu
Ostrander, Darin
Desai, Niraj
Kim, Min Young
Alasfar, Sami
Bloch, Evan M.
Tobian, Aaron A. R.
Garonzik-Wang, Jacqueline
Segev, Dorry L.
Avery, Robin K.
TRANSPLANTATION DIRECT, 2022, 8 (01): : E1268

← 1 2 3 4 5 →